U.S. FDA Approves Takeda ’s Takhzyro (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

Takhzyro is the First and Only Prophylaxis Treatment Approved in the U.S. for Children 2 to<6 Years of Age With HAE1-4 Approval Supported by Extrapolation of Efficacy Data From the Phase 3 HELP Study With Additional Data From the Phase 3...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news